Actinium Pharmaceuticals

U turn turn around refocus pivot street sign

FDA sinks Actinium's radiotherapy blood cancer filing plans

With the FDA requesting an additional head-to-head trial, Actinium is planning to try to partner the program and switch its attention to other assets.

Nick Paul Taylor Aug 5, 2024 8:12am

Vector Oncology chosen as Actinium’s CRO partner in PhII cancer trial

Sep 22, 2016 3:46am